The expansion of the transplant diagnostics portfolio is part of Immucor’s ongoing commitment to new advancements in the field of histocompatibility
The innovations will help Immucor in the advancement of histocompatibility field. (Credit: jarmoluk/ Pixabay)
Transfusion and transplantation diagnostic company Immucor has expanded its transplant diagnostics portfolio with two new additions.
The firm launched Mia Fora NGS Express HLA typing software that gives users of Mia Fora NGS MFlex HLA typing assays a faster and easier NGS analysis experience. It also enables the users to opt standard Windows desktop computing system in addition to the current Linux server.
The firm developed the Mia Fora software based on experience with HLA typing bioinformatics. Mia Fora along with the new Express uses three algorithms for the analysis of genotyping calls and a proprietary solution for precise mapping and alignment.
The system’s updated smart flagging system to make confident allele calls rapidly will give a faster total turn-around time for analysis.
The Mia Fora NGS Express HLA typing software is equipped with a CE mark and is available in the US for Research Use Only (RUO).
Immucor president and CEO Avi Pelossof said: “The launch of Mia Fora NGS Express showcases Immucor’s ongoing dedication and partnership to the transplant community and our investment in improving workflows for the rapidly evolving needs of the HLA testing community.”
The company also announced that the US Food and Drug Administration (FDA) has cleared Luminex single antigen product, Lifecodes LSA Class I and Class II Assays. It showed a lower false-positive rate which will enhance the clinical laboratory’s ability to find acceptable donors to provide new beginnings for more transplant patients.
Immucor chief marketing officer Christie Otis said: “This milestone highlights Immucor’s ongoing investment in our transplant antibody portfolio.
“We are proud to offer IVD cleared product for the US transplant community and plan to expand commercialisation of Lifecodes LSA to new markets supported through this regulatory investment.”